Drug Database
ME

meningococcal A conjugate vaccine (MenAfriVac)

✓ Approved

Serum Institute of India Pvt. Ltd. · Cell-based Therapies · Cell-based Therapies

What is meningococcal A conjugate vaccine?

meningococcal A conjugate vaccine is a cell-based therapies developed by Serum Institute of India Pvt. Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesMenAfriVac
CompanySerum Institute of India Pvt. Ltd.
Drug ClassCell-based Therapies, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Serum Institute of India Pvt. Ltd.

Therapeutic Indications

meningococcal A conjugate vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedHuman vaccines & immunotherapeutics2026-06-09

Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.

Hoberman Alejandro A, Atwi Jibran J, Silas Peter P, Prato Rosa R et al.

Meningococcal vaccination of adolescents/young adults is recommended in various countries, including the United States (US). This phase 3b, observer-blind study (NCT04318548) evaluated the safety, reactogenicity, and immunogenicity of serogroup B vaccine, 4CMenB, and quadrivalent conjugate vaccine, MenACWY-CRM, when co-administered to healthy individuals aged 16-18 y, as per US Advisory Committee on Immunization Practices recommendations. Adolescents, who had received MenACWY vaccination ≥4 y previously, were randomized (N = 940; 1:1:1) to one of three groups to assess co-administration versus 4CMenB and MenACWY-CRM administered alone. Co-primary objectives were to demonstrate the non-inferiority of antibody responses after concomitant administration to antibody responses after 4CMenB (two doses administered 2 months apart) and MenACWY-CRM (single dose), as measured by human serum bactericidal assay (hSBA). Vaccine safety and reactogenicity were assessed as another primary objective. The co-primary endpoints were met: the lower limit of 2-sided 95% confidence intervals for all between-group ratios of hSBA geometric mean titers was >0.5 for the concomitant administration group versus 4CMenB group and MenACWY-CRM group. hSBA data after two 4CMenB doses and one MenACWY-CRM dose showed comparable between-group geometric mean ratios versus baseline, and percentages of participants with 4-fold rises in titers and titers ≥lower limit of quantitation. The safety profile of 4CMenB co-administered with MenACWY-CRM was comparable with that of 4CMenB administered alone. In conclusion, 4CMenB and MenACWY-CRM co-administration was well tolerated in adolescents aged 16-18 y and immune responses were comparable versus administration of each vaccine alone, which is consistent with a previous study of co-administration in infants.

PMID 42262312
Read full article →
PubMedNPJ vaccines2026-06-09

Pre-clinical efficacy of a candidate outer membrane vesicle gonococcal vaccine in comparison with 4CMenB.

Freixeiro Paula P, Lewis Lisa A LA, Sánchez-Busó Leonor L, Unemo Magnus M et al.

Neisseria gonorrhoeae causes 82 million global cases of gonorrhoea annually. Multidrug-resistant gonococci threaten to make gonorrhoea untreatable. Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31-59% effectiveness. We hypothesised that gonococcal OMV-based vaccines would have greater efficacy against gonorrhoea than meningococcal vaccines. We developed native OMV (nOMV) candidate Neisseria vaccines from gonococcal strains GC_0817560 and FA1090, and meningococcal B strain NZ98/254. lpxL1 and rmp genes were deleted to reduce reactogenicity and minimise induction of unprotective or blocking antibodies. nOMV were characterised and formulated with aluminium hydroxide. Deletion of lpxL1 markedly reduced nOMV-induced IL-6 release from peripheral blood mononuclear cells. nOMV derived from GC_0817560lpxL1-rmp- and FA1090lpxL1-rmp- induced greater quantities of gonococcal-specific serum IgG and accelerated clearance of FA1090 from oestradiol-treated BALB/c mice significantly faster than 4CMenB and NZ98/254lpxL1-rmp- nOMV (P < 0.0001). Gonococcal nOMV-based vaccines represent promising candidates for further development.

PMID 42259835
Read full article →
PubMedInternational journal of biological macromolecules2026-06-09

Chrysanthemum-like nanodrug assembled from hyaluronan-doxorubicin/cisplatin conjugate for targeted synergistic chemotherapy of hepatocellular carcinoma.

Qian Junmin J, Li Yuhan Y, Chen Rui R, Wang Jinlei J et al.

Hepatocellular carcinoma (HCC) is usually diagnosed at advanced stages and has a high mortality rate and a short survival time, posing significant threats to human life and health. Chemotherapy remains the cornerstone of HCC treatment, but it still faces significant challenges of limited monotherapy efficacy and drug resistance. Herein, a stimulus-responsive hyaluronic acid (HA)-based dual-drug conjugate was proposed for efficient targeted synergistic chemotherapy of HCC. The amphiphilic conjugate (HDC) was synthesized by successively grafting doxorubicin (DOX) and cisplatin (CDDP) onto hydrazide HA (HHA) through labile hydrazone and coordination bonds, respectively. The resulting conjugate could self-assemble into well-dispersed chrysanthemum-like HDC nanoparticles with a hydrodynamic size of approximately 180 nm and a high drug content exceeding 30%. The HDC nanoparticles exhibited pH/glutathione dual-responsive drug release behaviors, effective tumor targeting via CD44 receptors-mediated endocytosis, and synergistic cancer cell-killing efficacy compared to equivalent-dose monotherapies. In vivo studies demonstrated remarkable tumor suppression and favorable biosafety. Overall, this work proposes a novel strategy that combines targeted co-delivery of DOX and CDDP with the ability to eliminate glutathione-mediated drug resistance, showing promising potential for clinical translation in HCC therapy.

PMID 42259411
Read full article →
PubMedHealth promotion international2026-06-09

Attitudes to mandatory COVID-19 vaccination in early life: findings from the multi-country cross-sectional CANDOUR study.

Porter Georgia G, Roope Laurence S J LSJ, Violato Mara M, Duch Raymond R et al.

We examined variation in attitude toward mandatory COVID-19 vaccination in early life by sociodemographic characteristics, personal COVID-19 experience, health risk attitude, political ideology, and other COVID-19 vaccine mandate attitudes. For this purpose, we used data from 19 928 participants from 16 countries surveyed in March-November 2022 for the second wave of the COVID-19 vaccine preference and opinion survey (CANDOUR). Analyses were adjusted for poststratification weighting. Participants who disagreed with early life mandatory COVID-19 vaccination were more likely to decline vaccination against COVID-19 (14.5%) compared with those who were neutral (1.8%) and those who agreed (0.5%). Disagreement with early life mandatory vaccination was associated with more unwillingness to take risks with their own health, being centre or left-wing on the left-right political spectrum, believing COVID-19 vaccination should be a personal choice, and being opposed to vaccine mandates for schoolchildren and the public. Neutrality or agreement with early life mandatory vaccination was associated with neutrality or agreement with a vaccine mandate for schoolchildren or a governmental COVID-19 vaccine mandate for everybody. Pandemic preparedness governance needs to focus on attitudes toward vaccine mandates. Further research and commitment by governments at various levels are needed to identify social, cultural, and system-level factors that could inform vaccination strategies to be implemented for the next pandemic.

PMID 42262063
Read full article →
PubMedTropical medicine and health2026-06-09

Persistence and booster response of rabies antibodies among health care workers with multiple vaccinations.

Castellano Mark Joseph MJ, Sornillo Johanna Beulah JB, Saito Nobuo N, Nishizono Akira A et al.

Rabies is a fatal but vaccine-preventable disease. Health care workers (HCWs) in endemic areas may receive repeated rabies vaccination because of occupational exposure, yet data on long-term antibody persistence and booster response after multiple prior vaccine regimens remain limited. This study aimed to determine the rabies antibody profile of HCWs previously vaccinated with rabies vaccine. We analyzed 126 HCWs from the Research Institute for Tropical Medicine (RITM) and Muntinlupa Animal Bite Treatment Centers (ABTCs) in the Philippines. Vaccination records were reviewed, and booster doses consisting of 0.1 mL purified Vero cell rabies vaccine (PVRV) were administered intradermally on days 0 and 3. Pre- and post-booster rabies antibody levels were measured using the rapid fluorescent focus inhibition test (RFFIT). All HCWs vaccinated within the previous year retained pre-booster antibody titers ≥ 0.5 IU/mL. Participants who had received three or more prior rabies vaccine regimens also maintained protective pre-booster antibody levels within 3-5 years after the last vaccination. After booster administration, all participants achieved antibody titers above the protective threshold ≥ 0.5 IU/mL, regardless of prior vaccination history or time since last vaccination. Repeated rabies vaccination was linked to sustained antibody persistence, while previous vaccination history was associated with preserved booster responsiveness among HCWs. These findings suggest that, in addition to time since last vaccination, the number of prior rabies vaccine regimens may help inform about the persistence of protective antibody levels in previously immunized individuals.

PMID 42260595
Read full article →
PubMedThe Lancet. Global health2026-06-09

Inclusion of young adolescents in policy development for new tuberculosis vaccines.

Hatherill Mark M, Clark Rebecca A RA, Martinez Leonardo L, Fiore-Gartland Andrew L AL et al.

The infant tuberculosis vaccine, BCG, prevents severe tuberculosis disease, but protection is rarely durable beyond childhood. New tuberculosis vaccines are being developed for the prevention of infectious pulmonary tuberculosis in older adolescents and adults, but younger adolescents have been historically excluded from clinical trials of new tuberculosis vaccines. Reasons to include young adolescents (aged 9-14 years) in tuberculosis vaccine policy development include the opportunity to vaccinate before the age-related increase in risk of tuberculosis disease, as well as increased rates of HIV acquisition and pregnancy, which are both independently associated with tuberculosis risk, and the opportunity to implement tuberculosis vaccination with delivery of other school-age vaccines, such as human papillomavirus. These advantages are offset by several challenges, including testing vaccine efficacy in an age group with low rates of tuberculosis case accrual; low rates of Mycobacterium tuberculosis sensitisation, which might compromise bridging of immune correlates of protection from adults; and modest modelled population impact of vaccination of young adolescents, compared with mass campaigns in older age groups with higher tuberculosis incidence. Notably, if a tuberculosis vaccine that was effective only in individuals who are infected with M tuberculosis was rolled out exclusively to young adolescents, the projected low population impact could take many years to detect. We propose that challenges to the inclusion of young adolescents should be considered explicitly in the development of tuberculosis vaccine policy, so that they do not risk exclusion from the direct benefits of vaccination. We describe an alternative efficacy trial design, which would leverage higher rates of tuberculosis case accrual after recent household tuberculosis exposure, to deliver both vaccine efficacy data and validation of an immune correlate of protection. This novel strategy, together with licensure data from older populations, might support rapid implementation of new, effective tuberculosis vaccines for young adolescents.

PMID 42259345
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal A conjugate vaccine